Valneva Snares Pfizer For Lyme Disease Vaccine Pact
French Biotech Banks $130m Upfront
Days after inking a COVID-19 collaboration with Dynavax, Valneva has linked up with Pfizer to drive its Lyme disease vaccine VLA15 towards Phase III trials.
Days after inking a COVID-19 collaboration with Dynavax, Valneva has linked up with Pfizer to drive its Lyme disease vaccine VLA15 towards Phase III trials.